Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1%

Healthcare

Page 8
  1. Jun 11, 2026 · 03:04 · 4587 · Routine +

    Curium Advances Japan Radiopharma Pipeline as Phase 2 Dosing Completes for 64Cu-PSMA-I&T

    Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

    01
  2. Jun 10, 2026 · 18:31 · BNXT · Neutral

    Cash-strapped sublingual drug delivery platform extends debt maturity amid critical liquidity crunch.

    BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants

    02
  3. Jun 10, 2026 · 09:01 · APTX · Routine +

    Record $1.3B life sciences IPO launches on TSX, valuing Canada's largest pharma at ~$5.6B.

    Toronto Stock Exchange Welcomes Apotex

    03
  4. Jun 10, 2026 · 08:00 · 4151 · Routine +

    Pipeline-driven biopharma advancing rare disease and oncology franchises with incremental clinical evidence and regulatory wins.

    Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL

    04
  5. Jun 10, 2026 · 02:35 · 4565 · Routine +

    AI-driven GPCR drug discovery platform accelerates pipeline through strategic consortium membership and milestone-driven revenue turnaround.

    Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

    05
  6. Jun 09, 2026 · 20:38 · APTX · Routine +

    APOTEX HEALTH CORP. FILES FINAL PROSPECTUS AND ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERING

    APOTEX HEALTH CORP. FILES FINAL PROSPECTUS AND ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERING

    06
  7. Jun 09, 2026 · 19:00 · ARC · Routine −

    Interim CEO appointed for 90-day strategic review amid negative equity and penny stock stagnation

    ARCPOINT ANNOUNCES APPOINTMENT OF PETER KENDALL AS INTERIM CHIEF EXECUTIVE OFFICER

    07
  8. Jun 09, 2026 · 18:00 · ONCO · Neutral

    Preclinical oncology developer advancing PNKP inhibitor CMC, but facing severe liquidity constraints and a prolonged bear market.

    Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology

    08
  9. Jun 09, 2026 · 17:31 · MDP · Routine +

    Medexus adds late-stage cell therapy to pipeline, but near-term value remains tethered to GRAFAPEX commercialization ramp

    Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada

    09
  10. Jun 09, 2026 · 09:05 · PINK · Routine +

    FDA-approved AI surgical imaging pioneer secures minor R&D grant as commercial ramp remains early-stage and cash-burn persists

    Perimeter Selected for INOVAIT Pilot Fund to Advance AI for Breast Cancer Surgery

    10
  11. Jun 09, 2026 · 08:31 · BUX · Routine +

    Metabolomics-driven liquid biopsy platform expands from blood to urine, securing US IP while navigating a tight pre-revenue balance sheet.

    BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform

    11
  12. Jun 09, 2026 · 08:23 · ALZI · Routine +

    Early-stage AI diagnostics IPO raises $4M to fund Alzheimer's screening R&D and commercialization.

    Alzai Health Corp. Completes Initial Public Offering

    12
  13. Jun 09, 2026 · 08:00 · BHC · Routine +

    Canadian drug plan LOI for PrOKEDI is a steady commercial step, but the stock's -6.5% drift into the print reflects broader pipeline and debt overhangs already discounted.

    Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI(TM) (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia

    13
  14. Jun 09, 2026 · 07:31 · BPC · Routine +

    Building compliant U.S. telehealth and compounding infrastructure ahead of pivotal July FDA PCAC review.

    The Precision Peptide Company Establishes Compliant U.S. Peptide Access with Telehealth and Prescription Infrastructure Partnership

    14
← Newer Older →